Skip to content
Screener

PP&E (Net) at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$325.99M-12.3%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$155.13M+38.6%
Arrowhead Research logo
Arrowhead ResearchARWR
$374.82M-2.6%
Wave Life Sciences logo
Wave Life SciencesWVE
$6.83M-24.4%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$3.96M-8.3%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$7.4M-17.7%

Other financials

Income statement

See full
Operating income-$125.3M-2.4%
Net income-$120.9M-4.8%
EPS (diluted)-$0.73+30.5%

Balance sheet

See full
Cash & equivalents$753.1M+59.5%
Total debt$168.7M+623%
Total equity$865.1M+29.3%
Total assets$1.1B+49.8%

Cash flow

See full
Operating cash flow-$144.9M-36.9%
CapEx$221.0K-77.5%
Free cash flow-$145.1M-35.8%

Valuation

See full
Market cap$4.83B+193%
Enterprise value$4.25B+231%

Returns & leverage

See full
Return on equity-58.9%-4.4pp
Debt / equity0.2×+0.2×
Current ratio19.9×-0.4×

Where this comes from

Reported directly by Dyne Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The source filing: Dyne Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 7:25 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-215702
Line itemMarch 31, 2026December 31, 2025
Marketable securities219,054217,193
Prepaid expenses and other current assets48,87116,025
Total current assets1,021,0271,126,587
Property and equipment, net23,68224,029
Right-of-use assets19,65220,742
Restricted cash and other assets15,58915,600
Total assets$1,079,950$1,186,958
Liabilities and Stockholders’ Equity

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dyne Therapeutics, Inc.'s PP&E (net)?
Dyne Therapeutics, Inc. (DYN) reported PP&E (net) of $23.68M in Q1 2026.
How has Dyne Therapeutics, Inc.'s PP&E (net) changed year-over-year?
Dyne Therapeutics, Inc.'s PP&E (net) increased by 312.1% year-over-year, from $5.75M to $23.68M.
What is the long-term trend for Dyne Therapeutics, Inc.'s PP&E (net)?
Over 5 years (2020 to 2025), Dyne Therapeutics, Inc.'s PP&E (net) has grown at a 65.3% compound annual growth rate (CAGR), from $1.95M to $24.03M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Ask your AI about Dyne Therapeutics, Inc.'s pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude